IL-12 Cytokine for Radiation Toxicity Mitigation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective agents for protecting against or mitigating radiation-induced damage, particularly in acute radiation syndrome and radiation therapy-related toxicity, especially in scenarios like nuclear disasters or cancer treatment, where immediate medical intervention is not feasible.
Innovation Solution
Administration of a therapeutically effective amount of substantially isolated IL-12 to protect systems, organs, or tissues from radiation damage, including before, after, or at various times following radiation exposure, to diminish the effects of ionizing radiation on bone marrow, lymphatic system, immune system, and other tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If radiation therapy is administered to treat cancer, then tumor control and survival improvement are achieved, but radiation-induced toxicity and damage to normal tissues occur
Solution Approach 1:
The patent uses IL-12 as an intermediary substance that mediates between radiation therapy and normal tissues. IL-12 is administered to patients receiving radiation therapy to protect normal tissues from radiation-induced damage while allowing the radiation to maintain its anti-tumor effect. The cytokine acts as a biological mediator that selectively protects healthy cells without interfering with radiation's ability to kill cancer cells.
Solution Approach 2:
The patent applies preliminary anti-action by administering IL-12 before or during radiation therapy to preemptively protect normal tissues. The cytokine is given in advance to establish protective mechanisms in normal cells before radiation exposure occurs, or concurrently to provide ongoing protection during the radiation treatment course, thereby preventing radiation-induced toxicity before it can fully develop.
2Ease of operation
If medical intervention is delayed in radiation disaster scenarios, then triage and resource allocation can be managed, but survival rates of victims decrease
Solution Approach 1:
The patent implements preliminary action by providing IL-12 treatment that can be administered in the field immediately after radiation exposure, before victims reach medical facilities. This preliminary intervention stabilizes victims and prevents acute radiation syndrome progression, allowing for extended triage windows and more organized medical resource allocation while maintaining high survival rates even with delayed definitive care.
Solution Approach 2:
The patent enables self-service by developing a treatment protocol that can be administered by non-specialist personnel in disaster scenarios. IL-12 administration requires minimal technical expertise and can be performed by paramedics or trained first responders, allowing victims to receive life-saving treatment during transport or in temporary field hospitals without requiring specialized radiation medicine expertise.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
IL-12 administration increases survival and restores normal cellular, tissue, and organ functions by inducing the production of erythropoietin and other cytokines, providing protection against radiation-induced damage even at protracted times post-exposure, and reducing toxicity associated with radiation therapy.
Implementation Method 1
IL-12 administration increases survival and restores normal cellular, tissue, and organ functions by inducing the production of erythropoietin and other cytokines
Data Source
AI summary
Aspects and embodiments of the instant disclosure provide therapeutic methods and compositions comprising interleukin 12 (IL-12) useful for treating radiation-induced damage in a subject. In particular, the instant disclosure provides methods and compositions for radiation protection and/or radiation toxicity mitigation for the treatment of acute radiation syndrome and radiation induced toxicity associated with the treatment of cutaneous T-cell lymphoma.